Breast cancer: Oral SERDs in ER+ BC. Part 2 - Treatment selection and beyond

episode

COR2ED - Oncology Medical Conversation not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

S13 EP18: We've sold our dogs 51 min · 18 Sep 2026 · Parenting Hell with Rob Beckett and Josh Widdicombe

Cover Ups In Iran | Unfiltered 45 min · 18 Sep 2026 · Truth in the Barrel with Amy McGrath

NPR News: 09-17-2026 8PM EDT 4 min · 18 Sep 2026 · NPR News Now

Fletch, Vaughan & Hayley's Lil Bitta Pod - 18th September 2026 3 min · 18 Sep 2026 · ZM's Fletch, Vaughan & Hayley

Report any issue

Source

Recorded06 Dec 2023

Publisherfeeds.castos.com ↗

Handlerec:7789280

Show notes

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments. Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in